<DOC>
	<DOCNO>NCT00005794</DOCNO>
	<brief_summary>RATIONALE : Perifosine may stop growth tumor cell stop blood flow tumor . PURPOSE : Phase I trial study effectiveness perifosine treat patient advance solid tumor .</brief_summary>
	<brief_title>Perifosine Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) perifosine load dose/maintenance dose schedule patient advance solid tumor . - Determine qualitative quantitative toxic effect drug patient . - Determine pharmacokinetics drug patient . - Investigate relationship pharmacokinetic parameter toxicity drug patient . - Determine recommend start dose phase II trial drug schedule patient . - Evaluate pharmacodynamic parameter peripheral blood lymphocyte drug administration patient . - Determine change MTD prolong administration ( 3 month , 6 month ) drug patient . OUTLINE : This dose-escalation study . Patients receive load dose oral perifosine 4 time day 4-8 dos follow daily maintenance dose . Treatment continue every 28 day absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate loading dos maintenance dose perifosine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxic effect . PROJECTED ACCRUAL : Approximately 20-30 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm locally unresectable metastatic malignancy consider incurable Refractory treatment know form effective therapy No clinically active CNS metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : 02 Life expectancy : At least 12 week Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal SGOT great 2.5 time upper limit normal Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 6 month study participation Maintaining reasonable state nutrition consistent weight maintenance No recent history weight loss great 10 % current body weight No frequent vomiting/poor alimentation No serious concurrent medical illness would preclude study therapy PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Patients progressive disease treat LHRH agonist , antiestrogens , antitestosterones least 3 month may remain agent best interest Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics At least 21 day since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>